Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
NCT07315373
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Immune Thrombocytopenia
Interventions
DRUG:
Zanubrutinib 80mg/d
DRUG:
High dose dexamethasone
DRUG:
Zanubrutinib 160mg/d
DRUG:
Zanubrutinib 240mg/d
Sponsor
Peking University People's Hospital